100 related articles for article (PubMed ID: 8049452)
1. Hepatitis C virus as a risk factor for the development of veno-occlusive disease of the liver.
Ljungman P; Hägglund H; Lönnqvist B; Sönnerborg A; Ringdén O
Blood; 1994 Aug; 84(4):1349-50. PubMed ID: 8049452
[No Abstract] [Full Text] [Related]
2. A 32-year-old man with hepatitis C who developed progressive liver failure after a bone marrow transplant.
Lyra AC; Brunt EM; Pincus S; Di Bisceglie AM
Semin Liver Dis; 2002 Feb; 22(1):103-8. PubMed ID: 11928083
[No Abstract] [Full Text] [Related]
3. No beneficial effects, but severe side effects caused by recombinant human tissue plasminogen activator for treatment of hepatic veno-occlusive disease after allogeneic bone marrow transplantation.
Hägglund H; Ringdén O; Ljungman P; Winiarski J; Ericzon B; Tydén G
Transplant Proc; 1995 Dec; 27(6):3535. PubMed ID: 8540088
[No Abstract] [Full Text] [Related]
4. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia.
Rozman C; Carreras E; Qian C; Gale RP; Bortin MM; Rowlings PA; Ash RC; Champlin RE; Henslee-Downey PJ; Herzig RH; Hinterberger W; Klein JP; Prentice HG; Reiffers J; Zwaan FE; Horowitz MM
Bone Marrow Transplant; 1996 Jan; 17(1):75-80. PubMed ID: 8673059
[TBL] [Abstract][Full Text] [Related]
5. Factor V Leiden mutation as a predisposing factor for veno-occlusive disease following BMT.
Ertem M; Akar N
Bone Marrow Transplant; 2000 May; 25(10):1110-1. PubMed ID: 10828876
[No Abstract] [Full Text] [Related]
6. Excess of veno-occlusive disease in a randomized clinical trial on a higher trigger for red blood cell transfusion after bone marrow transplantation: a canadian blood and marrow transplant group trial.
Robitaille N; Lacroix J; Alexandrov L; Clayton L; Cortier M; Schultz KR; Bittencourt H; Duval M
Biol Blood Marrow Transplant; 2013 Mar; 19(3):468-73. PubMed ID: 23220014
[TBL] [Abstract][Full Text] [Related]
7. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors.
Hasegawa S; Horibe K; Kawabe T; Kato K; Kojima S; Matsuyama T; Hirabayashi N
Bone Marrow Transplant; 1998 Dec; 22(12):1191-7. PubMed ID: 9894723
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic liver transplantation for hepatic veno-occlusive disease after bone marrow transplantation--clinical and immunological considerations.
Schlitt HJ; Tischler HJ; Ringe B; Raddatz G; Maschek H; Dietrich H; Kuse E; Pichlmayr R; Link H
Bone Marrow Transplant; 1995 Sep; 16(3):473-8. PubMed ID: 8535323
[TBL] [Abstract][Full Text] [Related]
9. [Percutaneous intrahepatic portosystemic shunting in the treatment of veno-occlusive disease of the liver after bone marrow transplantation].
Alvarez R; Bañares R; Casariego J; Echenagusía A; Simó G; Alvarez E; Serrano D; Díez-Martín JL
Gastroenterol Hepatol; 2000 Apr; 23(4):177-80. PubMed ID: 10863859
[TBL] [Abstract][Full Text] [Related]
10. [Fulminant hepatitis-like veno-occlusive disease of the liver after allogeneic bone marrow transplantation in acute lymphoblastic leukemia].
Naito H; Arioka H; Kobayashi R; Ishikawa Y
Rinsho Ketsueki; 1993 May; 34(5):656-61. PubMed ID: 8315837
[TBL] [Abstract][Full Text] [Related]
11. [Veno-occlusive disease after bone marrow transplantation: preventive effect of heparin].
Parquet N; Devergie A; Socié G; Ribaud P; Espérou H; Gluckman E
Ann Med Interne (Paris); 1997; 148(2):132-5. PubMed ID: 9238437
[TBL] [Abstract][Full Text] [Related]
12. Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation.
Copelan EA; Penza SL; Elder PJ; Ezzone SA; Scholl MD; Bechtel TP; Belt PS; Avalos BR
Bone Marrow Transplant; 2000 Jun; 25(12):1219-22. PubMed ID: 10871724
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation.
Frickhofen N; Wiesneth M; Jainta C; Hertenstein B; Heymer B; Bianchi L; Dienes HP; Koerner K; Bunjes D; Arnold R
Blood; 1994 Apr; 83(7):1998-2004. PubMed ID: 7511444
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for hepatic veno-occlusive disease after bone marrow transplantation: retrospective analysis of 137 cases at a single institution.
Kami M; Mori S; Tanikawa S; Akiyama H; Onozawa Y; Tanaka T; Okamoto R; Maeda Y; Sasaki T; Kaku H; Matsuura Y; Hiruma K; Sakamaki H
Bone Marrow Transplant; 1997 Sep; 20(5):397-402. PubMed ID: 9339756
[TBL] [Abstract][Full Text] [Related]
15. [Whole body irradiation].
Le Bourgeois JP; Ganem G
Pathol Biol (Paris); 1989 Feb; 37(2):156-8. PubMed ID: 2652070
[No Abstract] [Full Text] [Related]
16. Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study.
Lee JH; Lee KH; Kim S; Lee JS; Kim WK; Park CJ; Chi HS; Kim SH
Bone Marrow Transplant; 1998 Nov; 22(9):883-8. PubMed ID: 9827816
[TBL] [Abstract][Full Text] [Related]
17. Hepatic veno-occlusive disease following peripheral blood stem cell or bone marrow transplantation.
Salat C; Holler E; Hiller E; Pihusch R; Kolb HJ
Haematologica; 1999 Jun; 84 Suppl EHA-4():40-3. PubMed ID: 10907464
[No Abstract] [Full Text] [Related]
18. Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study.
Lau GK; Liang R; Chiu EK; Lee CK; Lam SK
Bone Marrow Transplant; 1997 Apr; 19(8):795-9. PubMed ID: 9134171
[TBL] [Abstract][Full Text] [Related]
19. [Association of porphyria cutanea tarda and hepatitis C virus].
Martín-Vivaldi Martínez R; Espinosa Aguilar MD; Sánchez Sanchéz-Vizcaíno J; Quintero Fuentes D; Nogueras López F; López de Hierro Ruiz M
Rev Esp Enferm Dig; 1996 Mar; 88(3):213-6. PubMed ID: 8645516
[TBL] [Abstract][Full Text] [Related]
20. Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.
Brice K; Valerie B; Claire G; Valerie M; Yves B; Gilles A; Nathalie B
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):135-43. PubMed ID: 17952879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
